Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
GR-system developer reports Q3 net loss of $6.7 million
December 12th, 2004
Depomed, Inc., (DEPO) announced its financial results for the quarter ended September 30, 2004. For the quarter, a net loss of $6.7 million or $0.19 per share was reported, compared to a net loss of $7.0 million or $0.27 per share for the comparable period in 2003. Total revenues for the third quarter of 2004 were $64,000 compared to $365,000 in the same period of 2003 as a result of a reduction in product-development services performed under collaborative research agreements. Revenue in the third quarter of 2004 included amortized license fees from a license agreement signed during the quarter with LG Life Sciences for the commercialization and...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
